Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery.
Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness. Dimenhydrinate is a combination of Diphenhydramine and 8-chlorotheophylline in a salt form, with 53%-55.5% dried diphenhydramine, and 44%-47% died 8-chlorotheophylline.
The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system while the excitatory effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade.
When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.
Dimenhydrinate was granted FDA approval on 31 May 1972.
Dimenhydrinate is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness.
University Hospital of Larisa, Department of Anesthesiology, Larissa, Thessaly, Greece
UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
UPMC Passavant, Pittsburgh, Pennsylvania, United States
Clinica de Alergia MarttiAntila, Sorocaba, São Paulo, Brazil
ISPEM, São José dos Campos, São Paulo, Brazil
Clinilive, Maringá, Paraná, Brazil
Kocaeli University, Kocaeli, Turkey
Anesthesiology Department, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Mount Sinai Hospital, Toronto, Ontario, Canada
Ste-Justine Hospital, Montreal, Quebec, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.